<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426033</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 681257-CS10</org_study_id>
    <nct_id>NCT03426033</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin</brief_title>
  <official_title>Phase 1, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open label, single sequence, two-treatment, two-period drug-drug
      interaction study to evaluate the effect of multiple doses of ISIS 681257 on the
      pharmacokinetics of a single dose of warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Actual">February 25, 2018</completion_date>
  <primary_completion_date type="Actual">February 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The plasma concentrations of warfarin and ISIS 681257 will be measured at each individual time point.</measure>
    <time_frame>Each day for days 1-10 and 15-45</time_frame>
    <description>To evaluate the effect of multiple doses of ISIS 681257 40 mg subcutaneous injections on the pharmacokinetics of a single oral dose of warfarin in healthy adult subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of ISIS 681257 by the incidence of treatment-emergent adverse events.</measure>
    <time_frame>45 days</time_frame>
    <description>To evaluate the safety and tolerability of multiple doses of ISIS 681257 40 mg subcutaneous injections when coadministered with a single oral dose of warfarin in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Time will be measured by testing blood samples at each individual time point.</measure>
    <time_frame>Each day for days 1-7 and 15-21</time_frame>
    <description>To evaluate the effect of multiple doses of ISIS 681257 40 mg subcutaneous injections on the pharmacodynamics (anticoagulant activity) of a single oral dose of warfarin in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio will be measured at each individual time point by comparing prothrombin time to the normal mean prothrombin time.</measure>
    <time_frame>Each day for days 1-7 and 15-21</time_frame>
    <description>To evaluate the effect of multiple doses of ISIS 681257 40 mg subcutaneous injections on the pharmacodynamics (anticoagulant activity) of a single oral dose of warfarin in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time will be measured by testing blood samples at each individual time point.</measure>
    <time_frame>Each day for days 1-7 and 15-21</time_frame>
    <description>To evaluate the effect of multiple doses of ISIS 681257 40 mg subcutaneous injections on the pharmacodynamics (anticoagulant activity) of a single oral dose of warfarin in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma concentrations of warfarin and ISIS 681257 will be measured at each individual time point.</measure>
    <time_frame>Each day for days 1-10 and 15-45</time_frame>
    <description>To evaluate the effect of a single dose of warfarin on the pharmacokinetics of a single subcutaneous 40 mg injection of ISIS 681257 in healthy adult subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Elevated Lipoprotein(a)</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Single dose of warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of warfarin administered to obtain pharmacokinetic information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin in combination with ISIS 681257</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 681257</intervention_name>
    <description>Xmg dose administered as a subcutaneous injection</description>
    <arm_group_label>Warfarin in combination with ISIS 681257</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>25mg tablet administered orally</description>
    <arm_group_label>Single dose of warfarin</arm_group_label>
    <arm_group_label>Warfarin in combination with ISIS 681257</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Motivated and available for duration of study and willing to adhere to protocol

          -  Males who are unable to procreate or agree to contraception throughout study

          -  Females who are postmenopausal or surgically sterile

          -  BMI between 18.5 and 30 kg/m2

          -  Weighing greater than or equal to 50kg

          -  Normal lab results

          -  No known diseases or significant findings on physical exam

        Exclusion Criteria:

          -  Females of childbearing potential

          -  Reactions/infection at injection site

          -  Hypersensitivity to any drugs or similar drugs to those used in the study

          -  Conditions or disease that may interfere with study drug

          -  Any significant diseases

          -  Known history or familial history of bleeding disorders

          -  Drug dependency or abuse

          -  Illness within 28 days

          -  Previous exposure to other investigational drug within 28 days

          -  Blood donations within 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3P 3H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

